retatrutide liver disease Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Retatrutide Subcutaneous Fat Loss Results:

Case reports with dual agonists like tirzepatide show proportional loss of skeletal muscle mass alongside body weight

Clinical trials show approximately 2040% of total weight lost with GLP-1 medications includes lean mass, comparable to dietary restriction and bariatric surgery

Poor sleep increases ghrelin (the hunger hormone) and decreases leptin (the satiety hormone), partially counteracting the appetite suppression from semaglutide

Most GLP-1 medications require a gradual dose titration

This limitation is especially important in PCOS, where improved natural conception may plausibly reflect restoration of ovulatory opportunity after weight loss rather than a direct fertility-enhancing effect of the drug itself